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ABSTRACT
Objectives: To explore pharmacist and nurse views
and experiences in educating patients regarding their
treatment safety and tolerability as well as the roles of
other professions in this regard.
Design: In this qualitative study, six focus group
discussions were conducted.
Setting: The National Center for Cancer Care and
Research in Qatar.
Participants: Eleven pharmacists and 22 nurses
providing direct patient care.
Results: Concepts related to three key themes were
drawn from the seeding questions and included factors
for determining the level of risk they communicated:
the specific treatment regimen in question; the patient;
and their assessment of the patient. Patient-related
considerations arose from additional subthemes; both
nurses and pharmacists described aspects related to
the perceived psychological health status of the patient,
as well as anticipated comprehension, as ascertained
by demonstrated education and language abilities. In
all discussions, it was noted that physician and family
non-disclosure of cancer diagnosis to the patient
profoundly influenced the nature of information they
provided. While a high level of cohesion in safety
communication prioritisation among these two health
disciplines was found, a number of pharmacists
asserted a more formal role compared to informal and
repeated teaching by nurses.
Conclusions: Nurses and pharmacists in this Middle
East healthcare environment were not reluctant to
discuss treatment side effects with patients and draw
on similar professional judgements in prioritising
treatment risk information. We found that they did not
always recognise each other’s informal educational
encounters and that there are opportunities to explore
increased collaboration in this regard to enhance the
patient care experience.
BACKGROUND
Cancer care is increasingly complex and must
draw on the distinct yet complementary skills
of various health disciplines. Patients must
not only contend with the realities of the
diagnosis and possible unfavourable progno-
sis, but also digest information related to
complex and often debilitating treatments.1 2
The support of a multidisciplinary team then
can be integral to addressing patient con-
cerns and facilitating information exchange.
In cancer care specifically, coordinated con-
tribution by diverse health professionals
increases delivery of evidence-based treat-
ment and improves patient satisfaction.3–5
Results from countless studies have high-
lighted the value of providing adequate infor-
mation to patients with cancer, which includes
reports of decreased depression and anxiety;
the promotion of self-care and adherence; as
well as increased patient satisfaction with
overall management.5–10 In particular, clinical
teaching regarding the side effects of treat-
ments and recommended management strat-
egies is information consistently ranked high
in importance by patients with cancer.11 12
Mental well-being was inversely related to the
number of unmet information needs related
to side effects and symptoms among long-term
survivors of cancer.10 Patients reflecting at the
conclusion of cancer treatment opined that
frank information related to medication intol-
erances would have decreased their fear asso-
ciated with chemotherapy.13 However, the
Strengths and limitations of this study
▪ Information thresholds for treatment risk com-
munication with patients with cancer can vary
across cultures, but little is known about prac-
tices in the Middle East.
▪ We used qualitative methodology to explore
nurse and pharmacist perspectives on patient
education regarding side effects and intolerances
of cancer therapy.
▪ Although we do not measure observational data
to support the self-reports, both health profes-
sional groups identified the need and means to
frame risks appropriately and expressed beliefs
in the patient’s right to such information.
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desired level of such detail is different across cultures and
very little of this work has been conducted among Arab
patients with cancer.14 15
The Middle East region is currently undergoing an
expansion of specialised oncology treatment centres to
address the rising incidence of cancer cases among their
populations.16 The coordination of care among healthcare
providers is experiencing a parallel evolution in these set-
tings. Implementation of effective and integrated multidis-
ciplinary team-based care for patients with cancer varies
throughout the Middle Eastern region.17 Both pharmacists
and nurses counsel patients on their medications in a
variety of settings during encounters with patients with
cancer in Qatar. They share responsibility to educate
patients with cancer about the safety of their medications,
but may be reluctant to offer detailed information regard-
ing treatment side effects for fear of provoking non-
adherence. A prior study among oncology nurses and physi-
cians has demonstrated that health professionals may under-
estimate the information needs of patients with cancer.1 13 18
Elsewhere, patients with cancer express a strong desire for
information, but how is this addressed by providers in a
Middle Eastern context? We sought to evaluate how phar-
macists and nurses counsel patients regarding the poten-
tial side effects of their therapy and identify healthcare
provider roles in this regard.
METHODS
A qualitative descriptive study design using focus group
discussion for data collection was employed and chosen
as an efficient and feasible means to record participant
views. Such dialogue permits extensive responses about
people’s knowledge, attitudes and views and often pre-
cedes and informs the development of other qualitative
means of seeking to determine individual opinions
(surveys, questionnaires).19
Pharmacists (n=32) and nurses (n=263) providing care
at the National Center for Cancer Care and Research
(NCCCR) in Qatar were invited by email to participate.
The research purpose and methodology were reviewed
verbally and in writing (consent form) with participants
attending the interviews at NCCCR. A topic guide was
developed following a comprehensive literature review
of reports of other qualitative and quantitative assess-
ments of education of patients with cancer pertaining to
chemotherapy (see online supplementary appendix 1).
The devised framework sought to explore consenting
participant views and experiences in educating patients
regarding the safety and tolerability of their treatment
and the roles of multidisciplinary members in this
regard. One author facilitated each interview with a
second in attendance serving as a field note-taker. At the
end of each discussion, participants were given the
opportunity to ask additional questions or make further
contributions. Following this closing, the facilitator and
note-taker conducted a debriefing exercise, whereby the
researchers confirmed the seating arrangement and
associated coding of the participants, reflected on par-
ticipant responses and finally any suggestions for improv-
ing subsequent data collection events.19 20 Each audio
taped focus group interview was conducted and tran-
scribed by one of the investigators and transcriptions
subsequently verified and finalised independently by a
separate author.
The qualitative analysis of interviews was supported by
NVivo10 (QSR International 2013) software. Transcripts
were read through several times by all primary investigators
to obtain the sense of the whole and then subjected to
latent content analysis. Using thematic content analysis,
the text was divided into words, sentences or paragraphs,
related to each other through their content and context as
units of meaning.19–21 The data were then coded and orga-
nised around interpreted subthemes and themes and
based on comparisons of their similarities and differences.
Working theories were consolidated by the primary investi-
gators based on relevant topic characteristics associated
with the means by which they prioritise and choose
adverse effect information to communicate to patients.22
FINDINGS
Six separate focus group discussions lasting approxi-
mately 30–45 min were conducted—three each for phar-
macists (n=12) and nurses (n=22; table 1).
Participants delivered patient care in inpatient and
outpatient settings at NCCCR. The mean duration of
experience in oncology care was 6.2 (SD 2.3) years for
pharmacists and 9.9 years (SD 3.9) for nurses.
Participants were first asked to name the important
adverse effects they would generally communicate to
patients in their care. All groups consistently chose spe-
cific intolerances most prevalent with chemotherapy
regimens: nausea, vomiting, diarrhoea; symptoms asso-
ciated with immunosuppression (fever, chills); hair loss;
and infertility. Nurses tended to emphasize infusion-
related reactions, such as flushing, hypotension and
breathing difficulties. Both cohorts stressed that they did
not share such side effects in isolation, but together with
reassurances of their management.
We will advise them, for example, most of these side
effects are reversible, and we have a lot of techniques to
Table 1 Focus group participants
Discipline Participants, n
Years in oncology
practice (mean, range)
Pharmacists
FG 1 3 6 (1–7)
FG 2 4 5 (3–6)
FG 3 5 7.5 (5–11)
Nurses
FG 1 8 10.25 (6–18)
FG 2 8 9.5 (2–18)
FG 3 6 10 (2–20)
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control, we have medication for nausea and vomiting.
(Focus Group 1, Nurse 2)
When prompted next to offer how they would prioritise
this communication, concepts and connections to three
main themes were identified, describing factors related to:
the specific regimen in question; the patient; and their
assessment of the patient. Patient-related considerations
were then further categorised into subthemes of health
status, psychological status and education (figure 1).
SPECIFIC REGIMEN
Nurses and pharmacists both indicate giving patients
information about the most common side effects that
was further augmented according to the specific drugs
in the particular protocol prescribed.
This [education] is starting from the protocol—we have
ABVD protocol, most of the patients, like 70–80%, have
severe vomiting during this chemo. (Focus Group 3,
Nurse 1)
The timing and location of drug administration also
influenced this exchange. Patients admitted to NCCCR
to receive the first cycle of parenteral chemotherapy rou-
tinely meet a member of the clinical pharmacy team
and nurse educator for counselling. Most of the bedside
nurses we interviewed identified only reinforcement of
precautionary measures then at this point of care.
We are teaching the patient immediately if he has any fever
or dizziness or anything, immediately to let us know, to go
for medical attention. (Focus Group 1, Nurse 4)
Participants in all discussions elaborated that the infor-
mation they disclosed was influenced by the sequence of
the encounter with the patient during the course of
their care.
Mostly I would start with the most common side effects and
things that they can see within the first week of treatment
and what are the things that they take precautions with, so
they will not have an impact on their life within the initial
cycles of chemotherapy. (Focus Group 3, Pharmacist 1)
It’s a continuous process starting from first time to the last
cycle… some [patients], they will get used to the informa-
tion from the past experience, the past cycle [and] some
will not. Some will be continuously asking and we have to
continuously answer. (Focus Group 2, Nurse 3)
PATIENT FACTORS
Health status
A great deal of consideration for patient factors further
directed the content of these health professionals’
patient education. Determining if the prescribed
regimen was curative or not, and if the patient was actu-
ally aware of his or her prognosis, were aspects very care-
fully weighed prior to patient interactions.
If a patient is taking doxorubicin, for example, and it is
very well known that it causes cardiomyopathy [that may
appear after two years] and the patient has life expectancy
up to six months, I will not worry him more, not bother
him with that side effect. (Focus Group 2, Pharmacist 5)
If the patient doesn’t know the diagnosis, you can’t start
talking about chemotherapy; however, we give them
information about side effects or how to manage it, but
not in a detailed way. (Focus Group 2, Pharmacist 2)
Most participants agreed that the counselling they
offered to patients was also in deference to the family’s
wishes and often involved non-disclosure of the medica-
tion’s indication.
Sometimes we have problems with chemotherapy. Some
patients, the relative doesn’t want to tell the patient. We
have one case actually—don’t tell the patient that this is
chemotherapy. (Focus Group 2, Nurse 7)
Figure 1 Conceptual diagram. Themes identified from focus group discussions.
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Psychological status
Both nurses and pharmacists described assuming a
reassuring role in the care of their patients. Recognising
the vulnerability of many patients with cancer receiving
treatment, they tailored their education accordingly.
You know our patients, they are afraid of the chemotherapy,
especially if we gave all the side effects at one time. At first,
give at least the common things. (Focus Group 3, Nurse 2)
Sometimes they [patients] say they are afraid and ‘I don’t
want to take the chemo’, so we should choose which side
effects and what information we should give. (Focus
Group 1, Pharmacist 1)
While a number of participants acknowledged con-
cerns that learning the risks associated therapy may dis-
suade patients from accepting treatment, a strong sense
of responsibility to prepare their patients for the inevit-
able adverse effects emerged.
For the young also we will prepare them if they have long
hair to start to cut, how to manage, because also body
image it’s very important at this age adolescence, teen-
agers or 13 even 20. If they are planning to have a baby
for young ladies for example, for surgery, for mastectomy,
we have to prepare them, we will not ignore this. (Focus
Group 1, Pharmacist 2)
The point is like this, if we explain, some patients they
are afraid, some patients they will not agree, but if you
don’t explain hair loss will be there, vomiting will be
there, nausea will be there… if you don’t explain it, once
it occurs they will question the doctor or the nurse, ‘why
you didn’t you tell us when we started?’. That’s the
problem. (Focus Group 2, Nurse 5)
Education
The versatility required for patient counselling was
underlined by several descriptions of communication
barriers with the diverse patient population in this
setting, including literacy and mismatch between the
care provider and the patient’s native language.
When you are explaining to the patient, you must know
the level of understanding; you will use the simplest lan-
guage you can. (Focus Group 2, Nurse 6)
Some patients are not well educated at all some patients
cannot read and write, so it’s difficult to explain about
neutropenia even about immunity in Arabic or English
or whatever language, so sometimes it’s very difficult to
educate. (Focus Group 1, Pharmacist 2)
Pharmacists further underlined the importance of
acknowledging prior teaching by other healthcare provi-
ders and the ability to adapt education to the expressed
needs of the patient.
We tell them that we know that you have received educa-
tion before but we need to know the extent of the
knowledge to make sure that you understand fully all the
aspects of the treatment side effects and to understand
where are the areas that we need to focus on with you.
(Focus Group 1, Pharmacist 3)
In the outpatient setting when you interview the patient
he might come up with side effect that is his big
concern. (Focus Group 2, Pharmacist 2)
Patient assessment
Determining the health and psychological status and
education level of patients with cancer is accomplished
through the professional judgement of participants. All
stressed the unique nature of each care provider–patient
therapeutic relationship and both nurses and pharma-
cists illustrated the straightforward yet effective interview
approach to ascertain the aforementioned elements
described.
Once you talk to them, you will be able to know whether
they are expecting very little information or the medium
or the vast. (Focus Group 2, Nurse 3)
Just ask the patient. We have a small conversation with
the patient before starting to mention anything about
the medication. We just have like a background conversa-
tion about the patient—what he knows from his phys-
ician, what he knows about his medication—according to
this we will build what we have to say. (Focus Group 2,
Pharmacist 3)
I would say also that two-way communication will also
facilitate the issue. I usually go to the patient and ask the
first question, ‘do you know why you are here today?’
(Focus Group 2, Pharmacist 4)
EDUCATION ROLES OF HEALTHCARE PROVIDERS
When participants were asked about their perceptions
regarding the roles of different health professionals in
explaining the adverse effects of cancer therapy, many
identified how the introduction is usually by the physician
who takes the patient consent for chemotherapy. Nurses
posited that while the physician should assume the
primary role in patient education, they would emphasise
important adverse effects and extend other advice over
the course of treatment, most notably patient reassurance.
The first time the doctor will [give information]—they
are not convinced, they still have the doubts. But we are
the front line, we will ‘chill’ them step-by-step. (Focus
Group 1, Nurse 3)
Pharmacists corroborated the nurses’ impression
about patients’ need for reinforcement following the
physician visits and a number described receiving phys-
ician referral for such patient counselling. Some
acknowledged the value of nurses as the front-line care-
giver in evaluating patient drug tolerability, but most par-
ticipants adhered firmly to their scope of practice as the
optimal medication educators.
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For example, it’s a weekend and there is no pharmacist
available in the word and the patient will be discharged
—she [nurse] just will sit the basic side effects. (Focus
Group 1, Pharmacist 3)
Meanwhile, nurses expressed a preference for pharma-
cists to give the complete medication education for
patients, yet recognised real limitations.
Practically, a nurses is the one being always with the
patient and they are the one to give more information,
what if there is some inquiry—at that time the doctor or
the educator or the pharmacist will not be there—of
course, they will ask us only so we are the one to give the
information. (Focus Group 1, Nurse 5)
DISCUSSION
A fundamental responsibility of healthcare providers is
to give timely and appropriate information to patients.
We found commonalities among the nurses and phar-
macists interviewed in the organisation and prioritisation
of safety information that they communicated to patients
with cancer in this setting. Both health professional
groups informed patients of the common adverse effects
to anticipate, but offered this education with relevant
context and reassurance. This demonstrates an effective
patient-centred style, taking an individual’s thoughts and
feelings into account as the information of patients with
cancer can be unique, change over the course of care
and with acceptance of their diagnosis.23
The body of risk communication research has
demonstrated that the way adverse effect information is
presented affects patient decision-making. In our discus-
sions, no pharmacist or nurse explicitly described giving
estimated numeric rates of side effects, although this
information may be contained in certain written materi-
als that sometimes accompany counselling patient
encounters. In such cases, it has been shown that patients
are often unable to correctly interpret their incremental
chance of experiencing an unfavourable event compared
to placebo, thus perceiving an overestimate of their total
risk.24 As expected, some nurse and pharmacist partici-
pants expressed a reluctance to discuss potential side
effects for fear that such information may alarm certain
patients and promote non-adherence. While it is true
that the disclosure of adverse effect risk has the potential
to result in unintended behaviour, it has been demon-
strated that people respond favourably when risk infor-
mation is framed positively (90% or 90 out of 100
patients WILL NOT experience the intolerance instead
of 10% of 10 out of 100 patients WILL).25 26 Other
research has shown beneficial effects on patient’s per-
ceived risk of adverse effects when use of personal terms,
such as ‘your symptoms’, as opposed to impersonal ‘the
symptoms’ are employed and when interpretations are
supported by visual (graphs, pictograms).24 Pharmacists
and nurses in our focus groups were generally not dis-
suaded from sharing risk information, but recognised
that the possibility of subsequent patient non-adherence
could be mitigated by choosing side effects patients
would most likely immediately experience and coupling
this information with education related to their
management.
The level of cohesion in safety education prioritised
by these two health disciplines may be surprising, given
the diversity of the expatriate workforce on which Qatar
relies for the delivery of health services. Different cul-
tures appoint different weights to information on
patients with cancer regarding diagnosis, prognosis and
treatment.14 We did not formally collect ethnic back-
ground in our study demographics, but the nursing
population in Qatar is predominantly Southeast Asian,
where in many of these countries the role of the oncol-
ogy nurse is established as a caregiver delivering treat-
ment and education, but they also face challenges with
cultural norms.27 As expected, pharmacists and nurses
both described efforts, and often creativity, in working
around medication counselling of patients unaware of
their cancer diagnosis. This convention has been
described elsewhere where the culture of non-disclosure
predominates. For example, in many Asian, European
and Latin countries, patients with cancer are not often
fully informed of their condition.14 28–30 However, this
approach is often found to be at odds with the wishes of
such patients when they are surveyed.12 31 Work explor-
ing preferences among Middle Eastern Arab populations
is only just emerging. In a study among Saudi Arabian
nationals with symptoms suspicious for malignancy who
were referred for cancer diagnosis, all rejected the with-
holding of information regarding diagnosis and the
majority (99%) wanted to know the benefits and adverse
effects of therapy. Level of education did not appear to
be a factor influencing participants’ desire for transpar-
ency as half of those participating were characterised by
investigators as illiterate.15
The pharmacists and nurses we interviewed conceiv-
ably use professional judgements drawn from a body of
experience in cancer care, which ranged from 8 months
to 20 years; however, we know that these assessments can
be incompatible with patient information priorities and
information preferences cannot be simply distilled
through a uniform cultural characteristic. At least one
instrument has been developed to aid efforts to systemat-
ically assess level of individual patient education and
information needs, but it is not known how widely it has
been adopted in clinical practice.32
The health professionals interviewed all viewed them-
selves as having important responsibilities in communi-
cating safety education, but some responses imply that
pharmacists may minimise the role of nurses.
Understanding each professional’s role can minimise
gaps in and ensure continuity of care, especially when
there exists an overlap in scopes of practice.33 The
current professional conditions are such that pharmacists
in this and some other Middle Eastern countries are
reshaping traditional care identities and may be
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concentrating on establishing their own expanded
autonomous roles.34 Inherent in their training, pharma-
cists traditionally have the most structured approach to
communicating information pertaining to drugs. Also, at
this care site, only a small number of nurse educators
have defined patient teaching roles and the pharmacists
would not necessarily witness patient follow-up with
bedside nurses. This ongoing informal reinforcement by
nurses is invaluable for continuity of care, especially as
patients often forget information over time.35 Both
groups agreed that the physician’s role in educating
patients is incomplete and attributed this to several
factors: low patient retention of information from that
first encounter with the physician; physician emphasis on
explanation of diagnosis and gaining consent to care;
physician discretion that the patient does not need or
wish to have the information; and finally lack of physician
time resulting in (communicated and uncommunicated)
delegation to other care providers.
The interpretation of our results is subject to the lim-
itations of all small-scale qualitative work; generalising
findings rests on theoretical, rather than, statistical infer-
ences. The six focus group discussions involved propor-
tionately more members of overall pharmacy personnel
(total staff 32) compared to nursing (total staff 263), so
it is possible that we did not exhaust all possible themes.
While participant numbers within our pharmacist
groups were smaller than traditionally recommended for
focus groups (<8 individuals), smaller or ‘mini-focus
groups’ may be advantageous in ensuring that all
members have an opportunity to contribute and offer
investigators greater insight.36
Our participants are from a single geographic area
and cannot be assumed to represent similar populations
regionally or otherwise. However, we feel that the con-
cepts arising from our work contribute to the dearth of
literature related to communication of medication safety
and tolerability information to patients with cancer by
multidisciplinary team members. Participants offered
recommendations to augment such education for
patients in this setting, many that are consistent with
patient-centred care concepts and recommendations
made in the National Cancer Strategy.37 Development of
a more formal structure should first further consider the
views of both physicians and patients in this setting and
not obviate the ability for informal education by provi-
ders throughout the patient care process.
CONCLUSION
Nurses and pharmacists in this Middle East healthcare
setting assume responsibilities in treatment risk commu-
nication with patients. They are not reluctant to discuss
side effects, but both disciplines draw on similar profes-
sional judgements in prioritising information and
framing the education to be most appropriate for the
specific patient. We found that they did not always recog-
nise each other’s informal educational encounters and
there are opportunities to explore increased collabor-
ation in this regard to enhance the patient care
experience.
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